Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (ASPRE-T)

ASPRE-T - Clinical Trial

World-leading women's health providers across Monash University, Monash Health Women’s, Jessie McPherson Private, and The Royal Women’s Hospital are collaborating with the Fetal Medicine Foundation (UK), which has funded an international trial to establish whether aspirin is beneficial in preventing pre-eclampsia in twin pregnancies.

With a single-minded purpose to advance the treatments available for women during pregnancy and ensure the highest level of care, the ASPRE-T study is an international multicentre randomised trial led by the Fetal Medicine Foundation (UK) and involving 43 hospitals worldwide.

We are inviting all women with twin pregnancies before 14 weeks of gestation to participate in a double-blind, placebo-controlled study aiming to investigate whether aspirin prevents pre-eclampsia in twin pregnancies.

Pre-eclampsia is a serious and potentially life-threatening pregnancy complication that is more common in multiple pregnancies (10-15%) compared to singleton pregnancies.
Currently, it is unknown whether aspirin use during pregnancy helps prevent the disease and avoid preterm delivery due to early pre-eclampsia in twin pregnancies.

ASPRE-T (Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial) has the following criteria:

Inclusion criteria

Women will be eligible to participate if they are:

  • pregnant with twins, less than 14 weeks gestation
  • viable pregnancy

Exclusion criteria

  • non-viable pregnancy
  • greater than 14 weeks gestation
  • monochorionic monoamniotic (MCMA) twins
  • diagnosed with fetal malformations at the 11-14 weeks ultrasound
  • twin pregnancy that started as a triplet or higher order multiple pregnancy
  • coagulation disorder
  • allergy or sensitivity to aspirin
  • severe asthma
  • are not willing to provide written consent

Findings from the ASPRE-T study will advance the care and wellbeing of pregnant women around the world.

How to get involved

Speak with your GP, Midwife, or Obstetrician. If you are eligible to participate, you must be able to travel to one of the participating hospitals for scans, which will be provided.

Alternatively, you can contact the trial directly:
Principal Investigator A/Prof Daniel Rolnik (Obstetrician) and Mrs Lisa Le Bec (Midwife)
E: aspret@monash.edu | Ph: 0456 409 087

Study details

  • Ethics Committee Project Number: HREC/82152/MonH-2022-341186(v3)
  • Recruitment start date:  Monday 15 April 2024
  • Recruitment end date: Thursday 25 December 2025
  • Local reference number: RES-22-0000-369A
  • Number of study visits: 4 visits

For additional information, please visit: www.fetalmedicine.org

Our Collaborators

Monash Health Women'sRoyal Women's Hospital